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BRIEF REPORT
Midbiotics: conjugative plasmids for genetic engineering of natural gut flora
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aUniversity of Jyväskylä, Department of Biological and Environmental Science, Nanoscience Center, Jyväskylä, Finland; bDepartment of
Biological Sciences, University of Helsinki, Helsinki, Finland; cDepartment of Genetics, University of Cambridge, Cambridge, UK
ABSTRACT
The possibility to modify gut bacterial flora has become an important goal, and various
approaches are used to achieve desirable communities. However, the genetic engineering of
existing microbes in the gut, which are already compatible with the rest of the community and
host immune system, has not received much attention. Here, we discuss and experimentally
evaluate the possibility to use modified and mobilizable CRISPR-Cas9-endocing plasmid as a tool
to induce changes in bacterial communities. This plasmid system (briefly midbiotic) is delivered
from bacterial vector into target bacteria via conjugation. Compared to, for example, bacterioph-
age-based applications, the benefits of conjugative plasmids include their independence of any
particular receptor(s) on host bacteria and their relative immunity to bacterial defense mechan-
isms (such as restriction-modification systems) due to the synthesis of the complementary strand
with host-specific epigenetic modifications. We show that conjugative plasmid in association with
a mobilizable antibiotic resistance gene targeting CRISPR-plasmid efficiently causes ESBL-positive
transconjugants to lose their resistance, and multiple gene types can be targeted simultaneously
by introducing several CRISPR RNA encoding segments into the transferred plasmids. In the rare
cases where the midbiotic plasmids failed to resensitize bacteria to antibiotics, the CRISPR spacer-
(s) and their adjacent repeats or larger regions were found to be lost. Results also revealed
potential caveats in the design of conjugative engineering systems as well as workarounds to
minimize these risks.
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Introduction
The possibility to engineer gut microbiome has
become a notable avenue of research. Restoration
of microbial balance in the gut can provide a cure
to a multitude of complex diseases. Nonetheless,
stable installation of foreign beneficial microbes in
the gut is problematic. Studies have shown that
dietary supplement bacteria (probiotics) disappear
from the community soon after their ingestion
ceases.1,2 This has led many teams to compile
bacterial cocktails that would establish a more
stable population within the gut.3 Also, the near-
complete replacement of gut flora has been used to
revert dysbiosis. This so-called bacterial transplan-
tation is an effective approach to cure especially
recurrent diarrhea caused by Clostridium
difficile,4-6 but could also be used to improve var-
ious other conditions.7 The composition of gut
flora is also sensitive to diet, and, for example,
increase of fiber can result in notable shifts in the
community composition.8 In some circumstances,
however, the possibility to modify the genomes of
existing bacteria in the gut could provide an alter-
native to remodel the system.
So far, the genetic engineering of bacterial com-
munities in situ has mainly focused on bacterioph-
age-based applications.9,10 Conjugative plasmids
offer an alternative route with differing engineering
qualities. They are circular antagonistic genetic ele-
ments that can mediate their own transfer from one
bacterium to another. In addition, these self-
transmissible plasmids can co-transfer non-
conjugative plasmids with appropriate oriT site.11
The relaxosome of the conjugative plasmid recog-
nizes the similar oriT site in non-conjugative plas-
mid and mobilizes it through conjugation.12 The
exact conjugation mechanisms vary between plas-
mids, but they all form a channel between the cells
through which the plasmid is usually transported as
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a single-stranded DNA molecule to the recipient
bacterium. Plasmids can be readily modified with
various molecular biology methods, thus providing
a relatively simple platform for carrying out in situ
genetic engineering of bacterial cells. Given that the
diversity of gut microbiota varies even between
genetically identical twins,13 the attempts to colonize
maladapted (engineered) bacteria within an already
established community can be a challenging if not an
impossible task. In this respect, the introduction of
an engineered mobile element into the existing com-
munity instead of relying on the establishment of an
entire bacterium provides a potential workaround
for deploying desired functionalities within the sys-
tem. Given the established concepts of probiotics
(health-promoting bacteria) and prebiotics (nutri-
ents that promote the growth of beneficial bacteria),
”midbiotics” (plasmid-probiotics in a sense) provide
yet an alternative form of biotic substances that can
be used to acquire beneficial changes in the gut flora.
Naturally, such plasmids have only limited use,
albeit, in certain instances, they may be even
a preferable choice over probiotics such as when
only particular genes need to be removed from the
community.
Plasmids are divided into incompatibility
groups (Inc) based on their potential to stably
coexist in a bacterial cell. In other words, two
plasmids that share the same Inc-group cannot
be maintained in a single cell indefinitely.
Conjugative plasmids also often encode entry-
exclusion mechanisms that prevent related plas-
mids from entering the cell. Due to these natural
features, the plasmids used for engineering should
be uncommon in the targeted flora. Naturally,
determining the existence of certain plasmid
types routinely from a heterogenous community
is a laborious task. Yet, certain antibiotic resis-
tance–conferring plasmids of Enterobacteriaceae,
for instance, are relatively rare in patients.
Indeed, in a metastudy, Carattoli reviewed the
prevalence of different resistance plasmid families
in Extended Spectrum Beta-Lactamase (ESBL)
strains.14 Among the rarest were IncP-type plas-
mids. Despite this, conjugative IncP-plasmids are
well-studied, they have a robust conjugation
machinery and a broad host range. As such, they
provide an example of potential backbones that
could be utilized for engineering purposes.
In bacteriophage-based applications, the genetic
material within the phage is replaced, and as it
infects a cell after the attachment to a specific
receptor on the host cell surface, it delivers the
genomic cargo into the bacterial host.9,10 Phage-
based tools have acquired notable attention and
are currently under development toward drugs.
The advantage of phages is that they have
a narrow host range, and thus, they target specifi-
cally only the desired fraction of the bacterial
community. Yet, bacteria rapidly become resistant
to phages, and phages cannot be easily used to
exert activity against even all variants of certain
species. In this regard, conjugative plasmids pro-
vide qualities that could be useful for alternative
and more generally applicable engineering pur-
poses. As noted above, conjugative plasmids are
usually delivered as a single DNA strand to the
recipient cell. The complementing strand is
synthesized in the recipient bacterium and thus it
contains all the host-specific modifications in the
nucleic acids.15 This way the host does not recog-
nize the incoming plasmid as foreign genetic
material, which, in turn, allows the plasmid to
establish itself into a natural community without
prior knowledge of the features of bacteria therein.
Additionally, unlike phages, conjugative plasmids
are not dependent on specific receptors on host
cells as plasmids require only cell-cell contact. And
once plasmid gets into natural bacteria, it can
further disseminate itself into the next host. The
transfer rate from one bacterium to another is, of
course, slower and less-precise than phage-
mediated delivery of DNA. This sets certain
boundaries for the utilization of plasmids.
Nevertheless, conjugative plasmids can provide
a broad host range for introducing genetic mate-
rial into the gut flora.
The advent of CRISPR-Cas9 editing has pro-
voked numerous studies where specific target
sequences within various host organisms are
modified,16 even enabling strain-specific elimina-
tion of bacteria from heterologous communities.10
Introduction of CRISPR-Cas9 editing components
into conjugative plasmids provides a potential
mean to remove unwanted genes such as those
conferring antibiotic resistance from diverse bac-
terial systems. ESBL carriage refers to non-
symptomatic colonization of the gut by bacteria
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which are resistant to a wide range of different
beta-lactam antibiotics.17,18 This is of major con-
cern, as beta-lactams are the most commonly used
class of antimicrobials, owing to their broad spec-
trum and minimal side effects. They are abun-
dantly administered to treat and prevent bacterial
infections during various medical procedures.
Over the past few decades, ESBL carriage has
become increasingly more common among long-
term hospitalized patients as well as in the
community.19 ESBL carriage serves as a reservoir
of resistance genes and significantly increases the
risk of clinical infections.20-22 As such, we here set
to evaluate the possibility to use conjugatively
transferred plasmids to induce the loss of ESBL
genes (located either in plasmids or in the chro-
mosome) from a bacterial community.
Results and discussion
We constructed a midbiotic system consisting of
a conjugative IncP plasmid RP423 and a mobilizable
pCas9 plasmid containing Streptococcus pyogenes–
derived CRISPR/Cas924 that targets conserved sites
in two different beta-lactamase genes via plasmid-
encoded CRISPR RNA (crRNA). Part of RP4 origin-
of-transfer (oriT) site was cloned into pCas9 plasmid
in order to make it horizontally transferrable by the
RP4-encoded relaxosome complex. Further, 543 bp
region, including the target site of the CRISPR/Cas9
system, was deleted from the beta-lactamase gene
blaTEM-2 of RP4 to prevent the system from self-
targeting. From now on, the RP4blaTEM−2Δ172−714 plas-
mid is referred to as delivery plasmid and the mod-
ified pCas9 as pCRISPR plasmid, crRNA/multi-
crRNA referring to spacer(s) targeting the beta-
lactamase gene(s).
A donor bacterium (Escherichia coli HMS174)
harboring midbiotic plasmids (delivery and
pCRISPR-crRNA plasmids) was cocultured
together with recipient E. coli strain (HB101)
carrying a conjugative ESBL-plasmid pEC15
that encodes blaTEM-52b target gene.25 The
transfer of these plasmids to ESBL-positive bac-
teria and the subsequent coexpression of endo-
nuclease Cas9 and crRNA should induce the loss
of resistance by guiding the Cas9 complex to
ESBL gene and create a double-stranded nick
within the target site (Figure 1a). Nicking
linearizes the plasmid and prevents its replica-
tion. Indeed, after 24 h, only approximately 1:10
000 transconjugants retained the resistance in
comparison to a control treatment lacking the
crRNA (Figure 1b). To rule out the possibility
that this might result from the unequal conjuga-
tion rates between pCRISPR-crRNA and
pCRISPR-control plasmid, both were conjugated
independently to a recipient HB101 lacking the
target plasmid (Figure 2a). Altogether, this sug-
gests that in principle the dispersal of such mid-
biotics in the bacterial flora would relatively
efficiently resensitize the ESBL-harbouring reci-
pients to beta-lactams. Yet, while this approach
appears promising in accelerating ESBL loss,
there are still potential obstacles to be taken
into account when specific genes are targeted
with Cas9. These obstacles would be relevant to
most in situ applications that seek to delete
specific functions from the community (and
sometimes in applications that attempt to intro-
duce them); hence, we decided to take a closer
look at the caveats and the realistic prospects of
midbiotic engineering.
In many cases, there can be multiple variants
of the genes that encode undesired phenotypes.
For example, there is no single guiding crRNA
sequence that would direct Cas9 to all possible
ESBL variants. However, all classes of beta-
lactamase genes share sequences that are usually
conserved within the class (Figure 3). Targeting
these sites would provide a broad activity against
the class regardless of specific knowledge of the
variant in any particular case. When various
crRNAs are combined into the same plasmid
similarly to spacer arrays of natural CRISPR
systems, several targets could be abolished with
a single pCRISPR plasmid. We tested this by
adding two crRNA coding sites separated by
a repeat into the pCRISPR plasmid. This
pCRISPR-multi-crRNA plasmid was then trans-
ferred into two bacterial strains each harboring
a different type of an ESBL gene (blaTEM-52b
and blaCTX-M-14). The plasmid exhibited the
activity against both ESBL types, leading to
a nearly 500-fold decrease in cell density in
treated bacteria compared to control, suggesting
that combination of crRNA sites could indeed be
utilized to achieve broad activity (Figure 1c).
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We further studied the individual bacteria that
appeared to have avoided the anti-ESBL effect
despite having been introduced with the midbiotic
system. In other words, some bacteria which had
received the pCRISPR-crRNA/multicrRNA
plasmid still retained the resistance to beta-
lactams (Figure 1b-c). Sequencing of CRISPR
spacer locus of these plasmids (8 escape colonies/
replicate/experiment) revealed that the observed
tolerance to the midbiotic treatment after 24
Figure 1. Midbiotic plasmids against ESBL-positive bacteria. (a). 1) Donor cell delivers midbiotic plasmid system (pCRISPR plasmid
and delivery plasmid both of which share the same origin of transfer site, oriT) via conjugation into recipient target cell that harbors
ESBL plasmid (pESBL). 2) After a successful delivery of the plasmids, the new host cell starts producing the components required for
CRISPR/Cas9-activity (endonuclease Cas9, crRNA and tracrRNA, encoded by pCRISPR). 3) Cas9 cleaves the ESBL gene based on crRNA
that is programmed to target a conserved region within the gene. 4) This results in degradation of ESBL plasmid. (b). Among the
transconjugants (Transc) receiving the pCRISPR-crRNA, a difference of nearly four orders of magnitude in ESBL-positive bacteria was
observed. Rec denotes the total number of recipient bacteria. Out of the survivors, the deletion of the spacer in the CRISPR locus of
pCRISPR-crRNA plasmid (white arrowheads) explained the loss of activity. The mean cell density (cfu/ml) is calculated from a total of
six replicates from two different experiments (n = 6). The black bars indicate the standard error of mean (SEM). (c). Transformation of
pCRISPR-multi-crRNA into target bacteria caused the cell density of HB101(pEC13) (blaCTX-M) to decline by two orders of magnitude
and HB101(pEC15) (blaTEM) by three orders of magnitude. The deletion of either one (green and yellow arrowheads) or both of the
spacers (blue arrowheads) resulted in the survival of transformants. Larger deletion in CRISPR locus was most likely the reason for
the unsuccessful amplification of some escape mutants, as the primer binding sites were located in the deletion (orange arrow-
heads). Some survivors contained the intact spacers, suggesting that Cas9 gene or the target sequence might carry mutations. The
mean cell density is calculated from three replicates (n = 3). The black bars indicate the standard error of mean (SEM).
Figure 2. Conjugation of midbiotic system. (a). The conjugation rates of pCRISPR-crRNA and pCRISPR-control plasmid are equal,
determined by measuring the mobilization frequencies after 24 h conjugation. Therefore, the presence of spacers does not itself
hinder the mobilization rate of the pCRISPR plasmid. The mean cell density was calculated from three replicates (n = 3). The black
bars indicate the standard error of mean (SEM). (b). After 72 h, the delivery plasmid was observed to conjugate independently
without the mobilizable pCRISPR-control plasmid, as the density of cells containing pCRISPR-control plasmid was two orders of
magnitude lower than cells with delivery plasmid. Also, when 90 colonies from delivery plasmid selection plate were streaked on
plate selecting for pCRISPR-control plasmid, none of them was observed to contain the pCRISPR-control plasmid. On the contrary, all
the 90 colonies with pCRISPR-control plasmid also contained the delivery plasmid. The mean cell density was calculated from three
replicates (n = 3). The black bars indicate the standard error of mean (SEM).
646 P. RUOTSALAINEN ET AL.
h was mainly due to loss of the beta-lactamase-
targeting spacer(s) and their adjacent repeat (see
the graphic illustration of spacer deletions in
Figure 1b-c). In some cases, however, we did not
succeed to amplify the crRNA coding region at all,
suggesting that a larger deletion might have
occurred within the region. On the other hand,
sometimes the crRNA site was unaltered, indicat-
ing potential changes elsewhere, such as mutations
in tracrRNA, Cas9 or PAM sequence.10
Nevertheless, the emergence of mutants may be
difficult to prevent, but in principle several copies
of the crRNA regions, for example, could be
included in the plasmid, hence allowing it to retain
its activity even if one of the sites is lost.
Another potential concern derives from the
separation of the midbiotic into two or more plas-
mids. It is possible that the delivery plasmid mobi-
lizing the pCRISPR plasmid goes ‘rogue’ and
spreads alone in the community, thus attenuating
the desired effect. We investigated this possibility by
cultivating midbiotic bacteria (harboring pCRISPR
control plasmid) together with ESBL-positive strain
for 72 h during which the culture was refreshed
once a day. All of the studied clones (90 colonies)
with the mobilizable pCRISPR plasmid also con-
tained the delivery plasmid. In contrast to this, all
bacteria harboring the delivery plasmid had lost the
pCRISPR plasmid (Figure 2b). This indicates that
the mobilizable pCRISPR plasmid is not always
delivered together with the conjugative plasmid,
thus requiring countermeasures to minimize the
probability of such events. There are at least two
possibilities to achieve this: either the pCRISPR
plasmid and delivery plasmid could be combined
into a single plasmid or the toxin–antitoxin system
could be separated so that the pCRISPR plasmid
carries the gene for antitoxin and the delivery plas-
mid encodes the toxin. In the latter case, the dis-
persal of the delivery plasmid alone would lead to
cytotoxic response and death of the recipient cell.
Conjugative plasmids are agents in natural
microbial communities, albeit not an inherent
part of any particular strain or species. In the
recent bloom in microbiota research, they have
so far been a seldom utilized tool for inducing
genetic changes in existing bacterial communities.
Plasmids could be used both to introduce desired
genes or remove existing ones. Whether they have
applications beyond laboratories is yet to be
demonstrated, and the possible spread of malevo-
lent traits via horizontal gene transfer may be
a deterrent against using plasmids for engineering
purposes. Indeed, the obvious risk in introducing
a conjugative plasmid into a bacterial community
is that the element may pick up an unwanted gene
and disperse it further into other hosts. Before
introduction into clinical applications, the resis-
tance genes of delivery plasmid should be deleted
to prevent dispersal of new resistance genes.
However, it must be noted that the communities
aimed to be engineered will nevertheless harbor
various types of mobile genetic elements, and,
thus, if there is notable selection within the popu-
lation for acquiring a particular gene, it is likely to
disperse anyway. In any event, if the plasmid used
for midbiotic-like engineering must be removed
Figure 3. Designing of guide RNA for conserved sites in beta-
lactamase genes. A potential obstacle in gene deletion by
midbiotic application is the diversity of the genes that need
to be targeted. By combining multiple spacers into a single
plasmid and selecting conserved sites within target genes, it is
possible to increase the coverage. As the beta-lactamase genes
belonging to the same class share conserved sites in nucleotide
level, these sites can be used to design spacers for CRISPR/Cas9
system in order to target several resistance gene variants with
a single spacer. Majority of the genes in class blaTEM (154)
contain the conserved target sequence (green bar). The target
sequence selected for the class of blaCTX-M genes (green bar)
is not as highly conserved as in the blaTEM class, only 52 genes
contain the exact sequence. Only one gene in blaTEM class has
a point mutation (red rectangle) in the first nucleotide next to
PAM (blue), whereas genes of blaCTX-M class have more varia-
tion in these nucleotides. These mismatches in the first seven
nucleotides next to PAM might hinder the recognition of the
target by Cas924 and thus the efficiency of the spacer.
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from the community, the plasmid-dependent bac-
teriophages could provide a way to induce direct
selection against the plasmid. However, while
in vitro experiments suggest that this would result
in plasmid loss,26,27 it is yet to be determined
whether this occurs also in vivo.
Overall, the fraction of the community that can
be engineered with conjugative plasmids is equal
to the fraction of the flora that receives them.
Studies suggest that plasmid dynamics and persis-
tence in a community is a complicated matter
where trophic levels and various characteristics of
plasmids, their hosts and the environment play an
indispensable role.28,29 Without extensive selection
for the midbiotic plasmid, it is unlikely to spread
to even all possible hosts. Therefore, as in the case
of ESBL carriage, the midbiotic system could be
considered as a booster which accelerates ESBL
curing rather than an outright treatment.
Sometimes, however, even a small fraction of engi-
neered bacteria may be enough, such as in the case
of making the midbiotics encode externally
secreted bacteriocins against unwanted bacterial
species. Yet, the overall improved understanding
of the survival conditions of plasmids can help us
find ways both to get rid of conjugative plasmids
and, if necessary, to facilitate their dispersal.
Nevertheless, while caution is necessary, the ability
to introduce or remove genes within natural bac-
terial communities is a real possibility that could
be considered as a potential tool for genetic engi-
neering of existing bacterial systems or, for exam-
ple, modification of gut microbe transplants prior
to their implementation.
Materials and methods
Plasmids, bacterial strains and culture conditions
In this study, the so-called midbiotic system consists
of the conjugative RP4blaTEM−2Δ172−714 plasmid
(delivery plasmid) and mobilizable pCas9 plasmid
(pCRISPR plasmid, a gift from Luciano Marraffini,
Addgene plasmid # 42876) encoding the S. pyogenes
CRISPR/Cas9 system24 with crRNA(s) targeting
conservative sites of different beta-lactamase resis-
tance genes in ESBL plasmids (Table 1). pCas9 was
made mobilizable by cloning RP4 oriT site12,30
(50980–51793 bps, amplified with primers
RP4oriT-F and RP4oriT-R, Supplementary Table 1)
into pCas9 digested with SalI (ThermoScientific;
Waltham, Massachusetts, United States) into region
spanning 7377–7486 bps. The phosphorylated ESBL-
gene-targeting crRNA oligonucleotides (2 µM each)
were first annealed together in 50 µl reaction with 1x
of T4 ligase buffer (New England Biolabs; Ipswich,
Massachusetts, United States) and 0.05 M NaCl by
heating first at 95°C for 5 min and then cooling it
down gradually (1°C/35 sec) to 20°C. Then, crRNA
insert was ligated into BsaI (ThermoScientific)
digested pCas9 plasmid by T4 ligase in T4 ligase
buffer (New England Biolabs; Ipswich,
Massachusetts, United States). In order to prepare
the pCRISPR-multi-crRNA plasmid, the multi-
crRNA insert was multiplied by PCR from
a synthetic plasmid (GenScript; Nanjing, China)
with primers spacer-multi-crRNA-F and spacer-
multi-crRNA-R (Supplementary Table 1). PCR pro-
duct was purified according to instructions of
Qiagen PCR purification kit before being ligated
(similarly as above) into the plasmid. The pCRISPR-
control plasmid was otherwise similar but lacked the
crRNA (Table 1). If not mentioned otherwise, all the
PCRs were done according to instructions of
Phusion Hot Start II High-Fidelity PCR mastermix
(ThermoScientific), except for an extended initial
denaturation (from 5 min to 7 min 30 s), using
C1000 Thermal Cycler (Bio-Rad Laboratories Inc.;
Hercules, California, United States). Both ESBL plas-
mids, pEC13 and pEC15, in recipient strains, origi-
nate from nosocomial isolates,25 and the conserved
sites of their respective beta-lactamase genes (Table
1) were selected as targets for the CRISPR/Cas9
system of pCRISPR plasmids.
All the bacterial cultures were grown at +37°C in
Luria Bertani Lennox-broth (LB)31 and, as necessary,
plated on LB-agar (1%) plates. When appropriate,
the following antibiotic concentrations were used:
rifampicin (50 µg/ml), streptomycin (25 µg/ml),
kanamycin (25 µg/ml), chloramphenicol (25 µg/ml)
and ampicillin (150 µg/ml). Liquid cultures were
shaken at 220 rpm.
Partial deletion of blaTEM-2 in RP4
The part of blaTEM-2 gene (172–714 bp) contain-
ing the crRNA target site was deleted from RP4 to
prevent the midbiotic system from self-targeting the
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delivery plasmid. The deletion was first created in
the RP4 blaTEM-2 gene cloned in pET24 plasmid
by polymerase chain reaction (PCR) using 0.2 µM
of primers deletion-F and deletion-R
(Supplementary Table 1) with elongation time (5
min 15 s) adjusted so that the plasmid without the
unwanted sequence was amplified with extension
rate 0.5 kb/min.32 As the deletion was confirmed
with agarose gel electrophoresis, pET24-blaTEM
-2Δ172–714 PCR-product was recombined back to
circular plasmid by Red/ET recombination in
recombineering-proficient E. coli strain GB08-red
RifR (Gene Bridges; Heidelberg, Germany) according
to the manufacturer’s instructions, with the excep-
tion of using 10 ng of DNA for transformation.
Briefly, the truncated blaTEM-2Δ172–714 gene
was amplified by PCR with primers delblaTEM2-F
and delblaTEM2-R (Supplementary Table 1).
Template of the PCR was removed by DpnI treat-
ment (ThermoScientific), and blaTEM-2Δ172–714
PCR product was purified from the gel according to
instructions of Qiagen’s Gel purification kit
(Hilden, Germany). RP4 plasmid containing the
deletion was obtained by recombining blaTEM-
2Δ172–714 PCR product into RP4 in GB08-redRifR
strain. This RP4blaTEM−2Δ172−714 was then conju-
gated from GB08-redRifR to BL21 Gold(pCRISPR-
crRNA) with a donor to recipient ratio of 2:1 in
3 ml and then cultivated at +37°C, 220 rpm, for 16
h. Transconjugant bacteria were selected on LB agar
plates with chloramphenicol-kanamycin selection.
The colonies were picked and transferred into LB
medium with same antibiotic selection as above and
cultivated overnight without shaking. The colonies
containing the deletion (RP4blaTEM−2Δ172−714) were
identified by negative selection by plating on LB
agar plates with and without ampicillin selection.
This RP4blaTEM−2Δ172−714 plasmid was conjugated to
HMS174 by incubating donor and recipient in ratio
1:1 in 5 ml cultivation for 2 h at +37°C, 220 rpm.
Transconjugants were selected by plating on LB
agar plates with rifampicin-kanamycin selection.
Midbiotic conjugation
The efficiency of the midbiotic plasmids in inducing
ESBL loss from the transconjugants was investigated
with the following setup. Before the experiments,
donors HMS174(RP4blaTEM−2Δ172−714)(pCRISPR-
crRNA) and control HMS174(RP4blaTEM−2Δ172−714)
(pCRISPR-control) and the recipient strain HB101
(pEC15) were cultivated overnight with antibiotic
selection. To mix the equal number of cells for con-
jugation experiments, the cell density (colony forming
units; cfu/ml) of all the cultures were determined
either by plating or bymeasuring the optical density at
OD595 (Multiskan FC, ThermoScientific; Waltham,
Massachusetts, United States). The experiments were
performed in two sets with slightly different concen-
trations of bacteria (see below), and each conjugation
setup was replicated six times in total. The recipient
strain (~3.0 × 105 cfu/ml in the first experiment and
~7.0 × 105 cfu/ml in the second) was mixed with the
donor (~1.0 × 105 cfu/ml in the first and ~2.0 × 106
cfu/ml in the second) and cultivated 24 h in 5 ml LB
without antibiotics. After the experiment, plating was
used to measure the cell density of transconjugants
(streptomycin-ampicillin-chloramphenicol), recipi-
ents (streptomycin-ampicillin), donors (rifampicin-
kanamycin-chloramphenicol in the first experiment
and rifampicin-chloramphenicol in the second) and
of the community (no antibiotics). Donor and recipi-
ent strains were distinguished by differing resistance
for rifampicin and streptomycin, respectively. The
presence of RP4blaTEM−2Δ172−714 was controlled by
kanamycin and the pCRISPR by chloramphenicol
selection. In order to observe the potential for differ-
ent midbiotic plasmids to disperse separately,
RP4blaTEM−2Δ172−714 and pCRISPR-control plasmid
were cultivated for 72 h during which the culture
was renewed daily by transferring 50 µl of culture
into fresh 5 ml LB medium. After 72 h, the density
of bacteria carrying either RP4blaTEM−2Δ172−714 or
pCRISPR-control plasmid and the total cell density
was determined by plating with appropriate antibio-
tics. From the total of 90 colonies (30 colonies/repli-
cate), we determined whether RP4blaTEM−2Δ172−714 or
pCRISPR-control plasmid containing colonies also
accommodated the other midbiotic plasmid.
The conjugation efficiencies of the pCRISPR-
crRNA and pCRISPR-control plasmid were deter-
mined to be equal by conjugating the plasmids into
HB101 without target ESBL plasmid. The donors
were mixed with the recipient in ratio ~1–1.65:100
in 5 ml LB and cultivated overnight in the absence
of antibiotics. The cell density (cfu/ml) of transcon-
jugants with pCRISPR plasmids (streptomycin-
chloramphenicol), recipients (streptomycin) and
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donors (rifampicin-chloramphenicol) as well as the
total cell density (no antibiotics) were determined
by plating.
pCRISPR plasmid with multiple ESBL targets
To test the activity of multi-crRNA, electroporation
was used to transform the pCRISRP-multi-crRNA
plasmid to ESBL-plasmid harboring strains.
Electroporation was performed according to the pro-
tocol in manual of recombineering-proficient E. coli
strain GB08-red (Gene Bridges; Heidelberg,
Germany). The optimal density was measured with
UV-mini-1240 UV-VIS Spectrophotometer
(Shimadzu; Kyoto, Japan) using 1.5 ml semimicro
cuvettes (Brand; Germany). A 6.5 × 105 cfu/ml of
HB101(pEC13) and 4.0 × 106 cfu/ml of HB101
(pEC15) strain were used for each plasmid transfor-
mation. Every plasmid transformation (pCRISPR-
multi-crRNA and pCRISPR-control) was conducted
in triplicates by using 20 ng of plasmid DNA. One
negative control, transformed with 1 µl of water, per
bacterial strain was done. The DNA concentration of
plasmids was measured according to the protocol of
QubitTM dsDNA HS Assay Kit (Invitrogen;
Carlsbad, California, United States) by using Qubit®
2.0 Fluorometer (Invitrogen; Carlsbad, California,
United States). Transformants were plated on LB
agar plates without antibiotics and with the combi-
nation of chloramphenicol and ampicillin. Negative
control was plated with and without chlorampheni-
col selection. The activity of different crRNA sites
was determined by counting the colonies on each
plate.
Target site selection
The conserved regions of the blaTEM and
blaCTX-M beta-lactamase genes for crRNA targets
were determined by aligning sequence samples of
these classes (obtained from the ResFinder 3.0
database)33 separately with MUSCLE algorithm
with default settings by Geneious 8.1.9
(Biomatters Ltd; Auckland, New Zealand). The
most conserved sites with the appropriate PAM
sequence were selected for the crRNA spacer
sequences.
Escape mutants
The survived escape mutant colonies from the
conjugation and transformation were re-isolated
by plating them on chloramphenicol-ampicillin.
Eight colonies/replicate, except two colonies per
control replicate (altogether 32 colonies/experi-
ment), were grown in LB media with chloramphe-
nicol-ampicillin at +37°C without shaking.
CRISPR locus of pCRISPR-crRNA, pCRISPR-
multi-crRNA and pCRISPR-control plasmid were
amplified with PCR using one bacterial colony as
a template with primers spacerseqF and
spacerseqR (Supplementary Table 1). PCR product
was purified from primers and nucleotides with
0.4 U of Exonuclease I (20 U/µl, ThermoScientific;
Waltham, Massachusetts, United States) and 0.4
U of FastAP Thermosensitive Alkaline phospha-
tase (1U/µl, ThermoScientific; Waltham,
Massachusetts, United States). These reactions
were incubated at +37°C for 20 min and then at
+80°C for 15 min in order to inactivate the
enzymes. Sequencing-PCR of ExoSAP-treated
DNA was performed with BigDye Terminator
v3.1 Cycle Sequencing kit (Applied Biosystems;
Foster City, California, United States) according
to the manufacturer’s protocol. The sequencing
reactions were purified using the protocol of
BigDye Terminator v3.1 Cycle Sequencing kit
except centrifugation was performed with 1109 ×
g and 100 × g and, before adding formamide,
samples were dried at +37°C for 10 min.
Sequencing was carried out with 3130xl Genetic
Analyzer (Applied Biosystems/HITACHI; Foster
City, California, United States). The basecalling
was performed with Sequencing Analysis
Software v6.0 (Applied Biosystems; Foster City,
California, United States), and the sequences
were analyzed for deletions or mutations in
CRISPR locus by mapping them against the origi-
nal sequence by using Geneious 8.1.9 (Biomatters
Ltd; Auckland, New Zealand).
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